$38.5bn Alcon buy puts Novartis in the lead for global eye care
This article was originally published in Clinica
Executive Summary
Pharmaceutical giant Novartis is to raise its shareholding in specialty eye care products manufacturer Alcon and execute the most expensive acquisition in medtech history.